➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
McKinsey
McKesson
Merck
Dow

Last Updated: October 23, 2021

DrugPatentWatch Database Preview

Claims for Patent: 8,686,026


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,686,026
Title:Solid compositions
Abstract: The present invention features solid compositions comprising amorphous Compound I. For instance, Compound I may be formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.
Inventor(s): Liepold; Bernd (Dossenheim, DE), Jung; Tina (Mannheim, DE), Holig; Peter (Waechtersbach, DE), Schroeder; Rudolf (Worms-Pfeddersheim, DE), Sever; Nancy E. (Arlington Heights, IL), Lafountaine; Justin S. (Chicago, IL), Sinclair; Brent D. (Grayslake, IL), Gao; Yi (Vernon Hills, IL), Wu; Jianwei (Libertyville, IL)
Assignee: AbbVie Inc. (North Chicago, IL)
Application Number:13/156,783
Patent Claims: 1. A solid composition comprising (1) dimethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-((2S,5S)-1-(4-tert-butylphenyl)pyrroli- dine-2,5-diyl)bis(4,1-phenylene))bis(azanediyl)bis(oxomethylene)bis(pyrrol- idine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate ##STR00002## or a pharmaceutically acceptable salt thereof, in an amorphous form; (2) a pharmaceutically acceptable hydrophilic polymer; and (3) a pharmaceutically acceptable surfactant.

2. The composition of claim 1, comprising a solid dispersion which includes: (1) said dimethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-((2S,5S)-1-(4-tert-butylphenyl)pyrroli- dine-2,5-diyl)bis(4,1-phenylene))bis(azanediyl)bis(oxomethylene)bis(pyrrol- idine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate, or said pharmaceutically acceptable salt thereof, (2) said polymer, and (3) said surfactant.

3. The composition of claim 2, wherein said polymer has a T.sub.g of at least 50.degree. C.

4. The composition of claim 3, wherein said surfactant has a HLB value of at least 10.

5. The composition of claim 4, further comprising another surfactant having a HLB value of below 10.

6. The composition of claim 3, wherein said solid dispersion is an amorphous solid dispersion which further comprises said surfactant.

7. The composition of claim 3, wherein said polymer is a homopolymer or copolymer of N-vinyl pyrrolidone.

8. The composition of claim 2, wherein said polymer is copovidone.

9. The composition of claim 8, wherein said surfactant is D-alpha-tocopheryl polyethylene glycol 1000 succinate.

10. The composition of claim 8, wherein said surfactant is sorbitan mono laurate.

11. The composition of claim 8, wherein said solid dispersion is an amorphous solid dispersion.

12. The composition of claim 8, where said solid dispersion is a solid solution which comprises said surfactant.

13. The composition of claim 1, further comprising another anti-HCV agent.

14. The composition of claim 1, further comprising an HCV protease inhibitor.

15. The composition of claim 1, further comprising an HCV polymerase inhibitor.

16. The composition of claim 1, further comprising telaprevir or boceprevir.

17. The composition of claim 1, further comprising an anti-HCV agent selected from the group consisting of ITMN-191, BI-201335, VBY-376, VX-500, PHX-B, ACH-1625, IDX136, IDX316, VX-813, SCH 900518, TMC-435, ITMN-191, MK-7009, IDX-PI, BI-201335, R7128, MK-3281, PF-868554, PF-4878691, IDX-184, IDX-375, PPI-461, BILB-1941, GS-9190, BMS-790052, ABT-333, and ABT-072.

18. The composition of claim 1, wherein said composition comprises at least two pharmaceutically acceptable surfactants, one having an HLB value of at least 10 and the other having an HLB value of below 10.

19. The composition of claim 6, wherein said composition comprises at least two pharmaceutically acceptable surfactants, one having an HLB value of at least 10 and the other having an HLB value of below 10.

20. The composition of claim 11, wherein said composition comprises at least two pharmaceutically acceptable surfactants, one having an HLB value of at least 10 and the other having an HLB value of below 10.

21. The composition of claim 12, wherein said composition comprises at least two pharmaceutically acceptable surfactants, one having an HLB value of at least 10 and the other having an HLB value of below 10.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
McKesson
Mallinckrodt
Baxter
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.